In light of Anavex’s announcement of its first entire clinical gene pathway data in patients with Rett syndrome, coupled with Mission Therapeutics’ recent fundraising of £25.2 million to progress the clinical development of its lead drug candidates, there has been increasing evidence of interest taking place towards broader disease groups with underlying pathogenesis from mitochondrial dysfunction.

This November, we will unite 60+ C-Level, Biologist, Preclinical, Translational, and Innovation-Scouting Leaders who are building on from the industry’s latest setbacks to innovate mitochondrial-targeting approaches and expand novel therapeutic opportunities. From cutting-edge research backed by academia to transformative pipeline updates from preclinical and clinical settings revealed by the industry, this is your chance to get involved and de-risk clinical development by discovering and validating biomarkers for defined endpoints.

DATES & VENUE
19 Nov - 21 Nov 2024, 9:00 am - 5:00 pm
#_REVIEWS

OTHER INFORMATION
Go to Event Website
Ticket pricing starts from:
Drug Developer Pricing - Conference + Workshop Day: USD 3497.00, Drug Developer Pricing - Conference Only: USD 2599.00, Not-for-Profit, Academic, Start-Up Pricing - Conference + Workshop Day: USD 2897.00, Not-for-Profit, Academic, Start-Up Pricing - Conference Only: USD 2199.00, Service Provider Pricing - Conference + Workshop Day: USD 4297.00, Service Provider Pricing - Conference Only: USD 3199.00
TOPICS | CATEGORIES






Advertisements